Lilly still waiting on once-weekly Byetta

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Is Eli Lilly and Co. about to have another Effient experience?

Lilly and its development partner are trying to get approval for a once-weekly version of the anti-diabetes drug Byetta. The new drug will be called Bydureon.

But the U.S. Food and Drug Administration last week pushed its self-declared deadline for rendering a decision on the drug to Oct. 22. The previous deadline was in March.

Bydureon is key for keeping Lilly competitive in the diabetes game. Earlier this year, the FDA approved a Byetta competitor called Victoza, which is manufactured by Lilly’s diabetes nemesis, Denmark-based Novo Nordisk N/S.

Victoza is a once-daily injectible medicine, compared with the twice-daily injections required with Byetta.

Analysts expect Byetta sales to peak this year at more than $800 million (although Lilly shares that revenue with San Diego-based Amylin Pharmaceuticals Inc.) and then start falling off. But they expect Bydureon sales to reach $800 million to $1 billion by 2015.

Lilly needs to ramp up any new drug as soon as possible so it can build up revenue before Lilly’s bestselling anti-psychotic Zyprexa faces generic competition in October 2011.

Lilly had hoped that the blood thinner Effient would help offset the loss of Zyprexa sales. But the FDA took a year longer than promised to render a decision on the drug. And, because of a severe warning about bleeding causes by the drug, sales so far have been paltry.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In